期刊文献+

C-erbB-2、p53、Ki-67与子宫内膜癌的相关性分析 被引量:4

Correlation analysis of C-erbB-2,p53,Ki-67 and endometrial carcinoma
下载PDF
导出
摘要 目的探讨人表皮生长因子-2(C-erbB-2)、抑癌基因p53(p53)、细胞核相关抗原Ki-67(Ki-67)与子宫内膜癌的相关性。方法选取2013年3月至2017年3月广东省东莞市人民医院保存的子宫内膜癌组织标本80例,同时选取正常子宫内膜标本80例,不典型增生子宫内膜标本80例,采用免疫组化染色法检测三种标本C-erbB-2、p53、Ki-67的表达。结果子宫内膜癌组织C-erbB-2、p53和Ki-67阳性表达率分别为61.25%、52.50%和68.75%,明显高于正常组织和不典型增生组织(C-erbB-2:χ~2值分别为51.23、17.07;p53:χ~2值分别为44.06、16.78;Ki-67:χ~2值分别为34.49、13.33,均P<0.05);不典型增生组织C-erbB-2、p53和Ki-67阳性表达率分别为28.75%、21.25%和40.00%,明显高于正常组织(χ~2值分别为12.17、16.78、5.70,均P<0.05);C-erbB-2表达与患者组织分级、肌层浸润、临床病理分期和分化程度有关(χ~2值分别为14.92、22.31、7.28、14.46,均P<0.05);p53表达与患者临床病理分期有关(χ~2=9.22,P<0.05);Ki-67表达与患者组织分级有关(χ~2=13.48,P<0.05);C-erbB-2表达与p53和Ki-67呈正相关(rs值分别为0.27、0.35,均P<0.05),p53与Ki-67呈正相关(rs=0.55,P<0.05)。结论子宫内膜癌组织C-erbB-2、p53和Ki-67表达明显升高,与患者临床病理特征有一定关系,值得进一步研究。 Objective To investigate the correlation between human epidermal growth factor-2(C-erbB-2),tumor suppressor gene p53(p53)and nuclear associated antigen Ki-67(Ki-67)and endometrial carcinoma.Methods Endometrial carcinoma tissues of 80 cases preserved in Dongguan People's Hospital of Guangdong Province from March 2013 to March 2017 were selected,and normal endometrial specimens of 80 cases as well as atypical hyperplasia endometrial specimens of 80 cases were selected.Expressions of C-erbB-2,p53 and Ki-67 were detected with immunohistochemical staining.Results The positive rates of C-erbB-2,p53 and Ki-67 in endometrial carcinoma tissues were 61.25%,52.50% and 68.75%,respectively,which were remarkably higher than those in normal tissues and atypical hyperplasia tissues(C-erbB-2:χ^2 value was 51.23 and 17.07;p53:χ~2 value was 44.06 and 16.78;Ki-67:χ^2 value was 34.49 and 13.33,respectively,all P〈0.05).The positive rates of C-erbB-2,p53 and Ki-67 in atypical hyperplasia tissues were 28.75%,21.25% and 40.00%,respectively,which were higher than those in normal tissues(χ^2 value was 12.17,16.78 and 5.70,respectively,all P〈0.05).The expression of C-erbB-2 was related to grading of tissue,invasion of muscle layer,clinical pathological stage and degree of differentiation(χ^2 value was 14.92,22.31,7.28 and 14.46,respectively,all P〈0.05).The expression of p53 was related to clinical pathological stage(χ^2=9.22,P〈0.05).The expression of Ki-67 was related to grading of tissue(χ^2=13.48,P〈0.05).The expression of C-erbB-2 was positively correlated with p53 and Ki-67(rsvalue was 0.27 and0.35,respectively,both P〈0.05),and p53 and Ki-67 were positively correlated(rs=0.55,P〈0.05).Conclusion The expressions of C-erbB-2,p53 and Ki-67 in endometrial carcinoma tissue are significantly increased,which are related to the clinicopathological features of patients with endometrial carcinoma,and they are worthy of further study.
作者 陈文姗 韦励 陈艳雅 吴雪薇 CHEN Wen-shan;WEI Li;CHEN Yan-ya;WU Xue-wei(Dongguan People's Hospital of Guangdong Province, Guangdong Dongguan 523000, Chin)
出处 《中国妇幼健康研究》 2018年第6期709-712,共4页 Chinese Journal of Woman and Child Health Research
关键词 子宫内膜癌 P53 C-ERBB-2 KI-67 相关性分析 human epidermal growth factor-2 (C-erbB-2) tumor suppressor gene p53 (p53) nuclear associated antigen Ki-67(Ki-67) endometrial carcinoma
  • 相关文献

参考文献5

二级参考文献41

  • 1Burzawa J K, Schmeler K M, Soliman P T, et al. Prospective evaluation of insulin resistance among endometrial cancer patients [J]. Am J Obstet Gynecol, 2011,204(4) : 351-355.
  • 2Bohilea R E, Anc6r V, Cirstoiu M M, et al. Project for the national program of early diagnosis of endometrial cancer part I [J]. J Med Life. 2015. 8(3):305-314.
  • 3Min6r L, Klabenesova I, Jandakova E. The importance of HE4 in differential diagnosis of endometrial cancer [J]. Ceska Gynekol, 2015, 80(4) :256-263.
  • 4Cappelletti'M R, Gnetti L, Sant-ini D, et al. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? [J]. Oncoscience, 2015,2 (6) :567-569.
  • 5Olson S H, De Vivo I, Setiawan V W, et al. Symposium on advances in endometrial cancer epidemiology and biology [J]. Gynecol Oncol, 2015, 138 (3) : 497-500.
  • 6MORICE P, LEARY A, CREUTZBERG C, et al. Endometrialcancer[J]. Lancet, 2016, 387(10023): 1094-1108.
  • 7FURRER D, SANSCHAGRIN F, JACOB S, et al. Advantagesand disadvantages of technologies for HER2 testing inbreast cancer specimens[J]. Am J Clin Pathol, 2015, 144(5):686-703.
  • 8SUBRAMANIAM D, HE A R, HWANG J, et al. Irreversiblemultitargeted ErbB family inhibitors for therapy of lung andbreast cancer[J]. Curr Cancer Drug Targets, 2015, 14(9):775-793.
  • 9WU J, ZHAO S, ZHANG J, et al. Over-expression of Survivinis a factor responsible for differential responses ofovarian cancer cells to S-allylmercaptocysteine (SAMC)[J].Exp Mol Pathol, 2016, 100(2): 294-302.
  • 10AKSOY R T, TURAN A T, BORAN N, et al. Lack of relationof Survivin gene expression with survival and surgicalprognostic factors in endometrial carcinoma patients[J].Asian Pac J Cancer Prev, 2014, 15(16): 6905-6910.

共引文献39

同被引文献49

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部